Vicore announces first human dosed with novel ATRAG, C106
· First healthy volunteer dosed with C106 in a phase 1 trial · C106 is the first new angiotensin II type 2 receptor agonist (ATRAG) from Vicore’s VP03 program · Topline data expected Q1 2023 Gothenburg, June 16, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces initiation of a first-in-human trial with the novel ATRAG C106. The trial is expected to read out during Q1 2023. Vicore’s C106 is the first of four advanced candidate drugs from the VP03